News Archives - Daewoong Indonesia

Daewoong Pharmaceutical Company Indonesia (DPCI) Acquires a License to Sell COVID-19 Test Kit in Indonesia

zpdaewoong — Mon, 21 Dec 2020 05:35:28 +0000

▲ Daewoong Pharmaceutical Company Indonesia announced on 22th that it acquired a license to sell ‘AccuraDtect’ SARS-COV-2 RT-qPCR Kit, a molecular test kit for COVID-19 in Indonesia.

– Plan to supply ‘AccuraDtect,’ the COVID-19 test kit with CE-IVD certification acquired from Europe to Indonesia
– Enable to produce results within 4 hours after sample collection…Expecting to strengthen responsiveness to COVID-19

Daewoong Pharmaceutical Company Indonesia (hereinafter referred to as DPCI) (CEO Sengho Jeon) that is developing COVID-19 treatment announced on 22th that it acquired a license to sell ‘AccuraDtect’ SARS-COV-2 RT-qPCR Kit, a molecular test kit for COVID-19 in Indonesia.

“As the spread of COVID-19 in Indonesia becomes more severe, the demand for COVID-19 test kits in every country is increasing rapidly,” said Sengho Jeon, CEO of DPCI. “With this approval for sale, we expect that the supply of the test kit can contribute greatly to improving Indonesia’s responsiveness to overcome COVID-19 pandemic by supplying Korea’s excellent PCR (Polymerase Chain Reaction),” he stated.

‘AccuraDtect’ is a highly sensitive COVID-19 molecular test kit that targets the leader sequence found most in infected cells in addition to the N2 gene, which is usually detected for COVID-19, to diagnose whether an individual is infected with the virus.

Under the standards recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the United States, AccuraDtect targets three biomarkers, which can identify the presence of coronavirus, RdRp, E and N2 and enables to produce results within 4 hours after sample collection.

In particular, it is designed to measure even Ribonuclease (RNase) P, which can determine the suitability of the sample and act as an infection spreader in the infected cells of virus. Furthermore, as it uses the gene amplification technique called real-time polymerase chain reaction (RT-qPCR) to amplify and detect virus genes, it has a high level of accuracy (including sensitivity and specificity).

This kit has obtained CE-IVD from Europe last March and emergency use authorization from Peru and Singapore.

Regarding this supply license, CEO Sengho Jeon at DPCI said, “We are planning to do our best effort to provide a total solution to overcome COVID-19 pandemic while successfully developing COVID-19 drugs niclosamide and chamostat, which are currently under development.”

Meanwhile, Daewoong Pharmaceutical Indonesia plans to quickly secure a local partner who will be responsible for the distribution of ‘AccuraDtect’ and supply it to Indonesia. ‘AccuraDtect’, a test kit for COVID-19, is the original developer of Genomictree, a Korean company specializing in developing non-invasive molecular diagnostics for the early detection of cancers based on the biomarker and Daewoong Pharmaceutical owns the global distributorship.

The post Daewoong Pharmaceutical Company Indonesia (DPCI) Acquires a License to Sell COVID-19 Test Kit in Indonesia appeared first on Daewoong Indonesia.

Joint Ventures build competitiveness in the industry… Turning COVID-19 Crisis into an Opportunity with Localization Strategy

zpdaewoong — Mon, 21 Dec 2020 05:24:54 +0000

▲.Daewoong Infion, a joint venture between the Korean pharmaceutical company, Daewoong Pharmaceutical, and Indonesian pharmaceutical company, Infion, donated personal protective equipment (PPE) for the COVID-19 clinical research to the clinical hospital on the 13^th.

– Joint ventures search for a breakthrough point of the economic crisis brought by the COVID-19 pandemic with localization strategy
– Daewoong Infion’s contribution towards the local pharmaceutical industry through technology transfer.. From the establishment of the first biopharmaceutical plant to stem cell COVID-19 treatment development research

The localization strategy of joint ventures to tackle the domestic economic crisis brought by the Coronavirus is drawing attention. The localization strategies of joint ventures are synergizing and creating LCR (Local Contents Requirement) policy to secure competitiveness in each industry.

Originally a policy for protecting the country’s industry, the securement of industry competitiveness through LCR is being supported by the government as a new strategy to boost the GDP forecast (-1.1% ~ +2.0) that has descended by the prolonged lockdown caused by COVID-19.

Daewoong Infion, a joint venture of Daewoong Pharmaceutical in Indonesia carrying out diverse activities for overcoming the COVID-19 crisis in Indonesia, claimed, “global corporations with technical competitive establishing joint ventures in Indonesia will be a great opportunity for both the local corporations and corporations advancing towards Indonesia.” They announced, “we will continue to strengthen our mutual growth model, as Indonesia will secure industry competitiveness based on advanced technology, and global corporations will be able to implement fast localization strategies.”

Daewoong Infion, the founder of Indonesia’s first biopharmaceutical plant,

From locally producing raw material medicine, EPO, to developing stem cell COVID-19 treatment

Daewoong Infion is a joint venture established in 2012 by Daewoong Pharmaceutical, a South Korean pharmaceutical company, and Infion, an Indonesian pharmaceutical company. Daewoong Infion opened Indonesia’s first biopharmaceutical plant in Surabaya and is carrying out biopharmaceutical research, development, and production in Indonesia with Daewoong Pharmaceutical’s outstanding biopharmaceutical technology transfer.

On the 13^th, Daewoong Infion held a ‘kick-off meeting for the phase 1 clinical trial of Daewoong COVID-19 treatment utilizing stem cells’ with the Ministry of Health at the ‘RSUP Dr. Wahidin Sudirohusodo’ hospital, then began the full-fledged clinical trial process. The phase 1 clinical trial will be held under the purpose of testing its safety upon COVID-19 patients, and aims to complete the trial within 2020 and enter the phase 2 clinical trial during the first half of 2021.

Daewoong Infion’s treatment for dyspnea symptoms caused by COVID-19 utilizing mesenchymal stem cell, DW-MSC, has received the first clinical approval in Indonesia as a stem cell treatment.

Daewoong Infion’s ‘DW710’ is under development with the active cooperation of the Indonesian Ministry of Health.

DWP710 called for the signing of a strategic cooperation MOU regarding COVID-19 treatments between Daewoong Infion and Indonesian Ministry of Health in July, and was approved for phase 1 clinical trial in July, followed by the selection as Indonesian Ministry of Health’s new project on August 6^th.

RSUP Dr. Wahidin Sudirohusodo hospital, where the clinical trials are held, has experience in implementing various global pharmaceutical clinical trials as a hospital specializing in COVID-19 treatment in Indonesia. In addition, Daewoong Infion supplied protective gear and clothing for the medical staff of the RSUP Dr. Wahidin Sudirohusodo hospital for the successful operation of the clinical trials, and made plans for further cooperation for the research and development of ‘Niclosamide’ and ‘Camostat,’ which are other candidate substances for COVID-19 treatment.

Chang-Woo Seo, the CEO of Daewoong Infion, said, “We thank the Indonesian government for their active cooperation for the development of COVID-19 treatment, and we hope this research could achieve good results and ultimately contribute as a treatment for overcoming COVID-19.”

COVID-19 treatment is not the only contribution towards the local pharmaceutical industry through technology transfer of Daewoong Infion. Daewoong Infion carries out a global production strategy through producing the undiluted ‘EPO’ solution in Indonesia and exporting it to Korea. Daewoong Infion produces the undiluted EPO solution and the finished product and sells the finished pharmaceutical product in Indonesia, whereas Daewoong Pharmaceutical imports the undiluted EPO solution from Indonesia to Korea to manufacture finished products. Daewoong Pharmaceutical’s EPO product is sold in Korea under the name “Eposis.” Daewoong Infion recorded 145 billion rupiahs worth of reverse export of undiluted EPO solution for three years, until the first half of 2020.

Meanwhile, Daewoong Infion is fostering Indonesia as a mecca of biopharmaceuticals through open collaborations with local universities and research institutions in Indonesia, carrying out research for searching new bio medicines and clinical research on EPO (Product name: Epodion). In 2017, Daewoong Infion received ‘The Best Biopharmaceutical Company’ award by Indonesia’s Ministry of Food and Drug Safety (BPOM) as well as the Minister’s Award from Indonesia’s Minister of Health and Welfare in November of the same year.

The post Joint Ventures build competitiveness in the industry… Turning COVID-19 Crisis into an Opportunity with Localization Strategy appeared first on Daewoong Indonesia.

Bio Regenerative Industry Issue Keyword, ‘Stem Cells’ – From COVID-19 Treatments to Bone Regeneration

zpdaewoong — Wed, 09 Dec 2020 09:06:45 +0000

▲ Daewoong Infion, a joint venture of South Korean pharmaceutical company Daewoong Group in Indonesia, held a kick-off meeting with RSUP Dr. Wahidin Sudirohusodo to initiate the study of DW-MSC for COVID-19 treatment.

– Active initiation of COVID-19 treatment development based on ‘DW-MSC,’ an independent technology amplifying stem cell’s effects

– Looking forward to the innovative contribution to treat incurable bone defect diseases with ‘Novosis,’ a bone-forming protein medical device

‘Stem Cell Treatment,’ which is expected to be the next-generation cell treatment to overcome various incurable diseases, is rapidly rising as a keyword of the bio-regenerative industry. With the prolongation of the Coronavirus (COVID-19) pandemic being inevitable, research in the stem cell• regenerative medicine field is expected to be significantly active.

According to the ‘Global Stem Cell Market Forecast 2017-2025’ report published in 2017 by InkWood, a research company, the global stem cell market is expected to grow rapidly, starting from $62.8 billion in 2017 and continue its growth to $394.4 billion in 2025. With the increase in clinical trials on stem cell treatment and other technology and the revitalization of new drug development based on stem cells, the global stem cell market is expected to steadily expand with an average annual growth rate of 25.8% (’17-’25).

A total of 7 stem cell treatment products have been released in the global market, but the stem cell treatments in the market tend to have low satisfaction rates on its effects compared to its price. Currently, many pharmaceutical corporations are continuously striving to improve the regenerative medicine field by reducing costs through establishing a mass production system and fostering indications with outstanding treatment effects.

Daewoong Pharmaceutical, a global healthcare corporation in Korea, introduced its stem cell platform ‘DW-MSC’ to develop new treatments for restoring tissue functions, such as organ damages that are not treatable with medicine alone and neurodegenerative diseases. DW-MSC has superior competitiveness along with high future utilization tendencies with its availability for stem cell technology industrialization and various industry technology combinations. Since 2018, DW-MSC’s safety in the human body has been proven by the toxicity and tumorigenicity assessment by the GLP (Good Laboratory Practice) certification institution.

Another advantage of DW-MSC is that the mass production of stem cell treatment of certified quality can be possible as it produces stem cells that originated from one-donor cells that passed strict quality assessments. This is a technology first introduced domestically by Daewoong Pharmaceutical, which is expected to maximize the effect of commercialization and distribution of stem cells.

Daewoong Pharmaceutical is establishing a cGMP level production facility for the production and development of cell treatments to apply stem cell platform technology by the second half of 2020, and is expected to enter the stage of production capability from 2021. In addition, it is receiving positive reviews in terms of commercialization and securing the competitiveness of the stem cell treatment since it is manufactured in a form that can be frozen and stored for immediate use for patients in the hospital.

Daewoong Pharmaceutical’s differentiated stem cell platform technology has been acknowledged by external experts for its value and is actively carrying out ‘Open Collaboration’ domestically and internationally. Open Collaboration refers to an open innovation strategy for combining ideas and technologies through cooperation with experts in the particular field, business partners, and the government.

“Cooperative research of clinical researchers is a vital success factor in the development of stem cell treatment,” Jeon Seung-ho, CEO of Daewoong Pharmaceutical said. “We aspire to lead the new drug development in the cell/genetic treatment field to improve quality of life through co-research with stem cell researchers from different fields by securing growth factors, stem cell cultivation technology, and GMP equipment with high researcher demands.”

Daewoong Infion leading the pharmaceutical industry with ‘DWP710,’ a treatment for COVID-19’s dyspnea symptoms utilizing DW-MSC

‘Daewoong Infion (CEO: Chang-woo Suh),’ Daewoong Group’s joint venture in Indonesia, announced the initiation of clinical trials for ‘DWP710,’ a treatment for COVID-19’s dyspnea symptoms utilizing ‘DW-MSC,’ an independent technology regarding stem cells.

“The stem cell COVID-19 treatment, ‘DWP710’ entered the clinical trial process through a kick-off meeting with the Ministry of Health on the 13^th,” said Nova Angginy, chief researcher at Daewoong Infion.

Daewoong Infion explained the clinical protocols of ‘DWP710’ and Daewoong Group’s stem cell technology ‘DW-MSC’ and delivered protective gear for supporting COVID-19 treatments at the meeting. ‘DW-MSC’ is Daewoong Group’s advanced technology amplifying the effects of stem cells, utilizing serum-free and xeno-free materials in the mesenchymal stem cell cultivation process, proved its effects on treating infection and inflammation from viruses, bacteria, and wounds through various inflammatory ability assessments.

Daewoong Infion aims to enter phase 2 clinical trials of ‘DWP710’ by the first quarter of 2021. Under the emergency authorization process based on the active cooperation of the Indonesian Ministry of Health, Daewoong Infion plans to swiftly distribute treatments after the completion of phase 2 clinical trials to overcome COVID-19. Daewoong Infion’s ‘DWP710’ was authorized of its phase 1 clinical trial last month, and was selected as the ministry of health’s cooperative project on the 6^th.

The clinical trial will be conducted at ‘RSUP Dr. Wahidin Sudirohusodo’ hospital, which specializes in COVID-19 treatment with diverse experience in global clinical trials on pharmaceutics, and will recruit patients from the third week of August to secure the phase 1 results by October. It aims to submit the phase 2 clinical trial proposal for approval in Republic of Korea and Indonesia.

Meanwhile, Daewoong Infion decided to conduct research and development of COVID-19 treatment candidates apart from ‘DWP710,’ ‘Niclosamide’ and ‘Camostat’ with the cooperation of ‘RSUP Dr. Wahidin Sudirohusodo’ hospital. The two products are anticipating effects on treating mild and severe COVID-19 patients.

Anticipation for regenerative treatment on bone damage with ‘Novosis,’ a bone-forming protein medical device

Novosis, a bone-forming protein medical device, is a carrier-based synthetic bone graft combining bone stimulating protein rhBMP-2 (recombinant human bone protein-2), which helps to differentiate stem cells in the human body into bone cells when bones are damaged, thereby facilitating the creation of new bones.

Novosis was developed through 13 years of research to surpass the bone-forming protein-based bone regenerative treatment, ‘Infuse,’ which is monopolized by a global medical device conglomerate, Medtronic. Patients with severe bone defects were able to receive treatment at a reasonable price thanks to the bio integrative medical device with increased effectiveness and maximized safety by applying CGBIO’s advanced protein carrier technology.

The rhBMP-2 used in Novosis has been recognized by the World Health Organization (WHO) for its technological innovation and original technology. A case in point was a child patient with an unfamiliar disease called osteoporosis, who had a severe deformity in his left leg at age 8. Extensive gelding of the leg bones was required in order to treat this patient, which would have left a permanent, non-walkable disorder.

However, the result of the new surgery using stem cell therapy and Novosis was successful, and the patient was able to return to a healthy lifestyle where he could enjoy active sports on top of walking. The doctor who performed the surgery is using the new treatment option of Novosis to treat patients whose treatment was too difficult with prior technology, such as incurable osteomyelitis and disjointed patients.

The post Bio Regenerative Industry Issue Keyword, ‘Stem Cells’ – From COVID-19 Treatments to Bone Regeneration appeared first on Daewoong Indonesia.

Daewoong Pharmaceutical obtains approval for clinical trials of the COVID-19 drug ‘Niclosamide’ in Korea

zpdaewoong — Wed, 09 Dec 2020 08:45:30 +0000

– Accelerated development with approval of clinical trials in Korea on the 8^th… Phase 1 clinical trials of COVID-19 drug go smoothly in India and the Philippines

– Aim to apply for Accelerated Approval and Emergency Use Authorization after planning to enter multi-national Phase 2 and 3 clinical trials and securing results of Phase 2 clinical trials within this year

– Confirmed a mortality rate of 0% and the effect of improving clinical symptoms even in the influenza virus, which concerns to cause ‘twin-demic’ other than COVID-19

Daewoong Pharmaceutical(CEO Sengho Jeon) and Daewoong Therapeutics(CEO Min-Seok Lee), a subsidiary of Daewoong Co., Ltd., announced the new coronavirus infection(COVID-19) treatment ‘DWRX2003(Niclosamide, the ingredient name)’ obtained approval for Phase 1 clinical trials in Korea from the Ministry of Food and Drug Safety (hereinafter MFDS) on the 8th.

Daewoong Pharmaceutical is currently conducting clinical trials of the COVID-19 stem cell treatment ‘DWP710’ in Indonesia, and is conducting Phase 2 clinical trials of Camostat(Foistar), which is expected to show therapeutic effects on mild and moderate COVID-19 patients, in Korea and Mexico.

Phase 1 clinical trials of “DWRX2003”(Niclosamide, the ingredient name) in Korea will be conducted at Chungnam National University Hospital on healthy subjects, and administration will begin in October. In clinical trials, Niclosamide or placebo will be randomly assigned, double-blinded, placebo-controlled, and administrated for a single time to confirm safety and maintenance of drug concentrations in the blood.

Daewoong Pharmaceutical is also accelerating global development by carrying out the first phase of clinical trials for “DWRX2003” in India and the Philippines, including Korea. In India, Phase 1 clinical trials are in progress for healthy individuals, confirming safety in the first group of medications, and clinical trials for the second group are in progress smoothly. In the Philippines, it is predicted to simultaneously explore the safety and treatment effects by conducting Phase 1 clinical trials for COVID-19 patients. Daewoong Pharmaceutical plans to enter Phase 2 and 3 of multi-national clinical trials within this year based on the results of Phase 1 clinical trials, and will immediately apply for Accelerated Approval and Emergency Use Authorization once the results of Phase 2 are secured.

Niclosamide is known as a mechanism drug that can inhibit both penetration and excretion of viruses into human cells. DWRX2003 is a product developed by Niclosamide as a sustained release injection using Daewoong Group’s proprietary drug delivery technology. △It overcomes the low absorption rate of oral administration. △ It is expected to maintain the concentration that can treat viral diseases only with a single administration. △It has the advantage of avoiding the side effects of the digestive system (nausea, vomiting, etc.) that occur when administered orally.

Meanwhile, Daewoong Pharmaceutical also confirmed the effect of influenza-induced mortality in the animal efficacy test of ‘DWRX2003’, which is developed as a treatment for novel coronavirus infections. The animal testing was conducted due to the cases of simultaneous infection of COVID-19 and influenza, and the continuously raised concerns of ‘twin-demic’ around the world.

The animal efficacy test for Niclosmaide confirmed that 40% of the placebo-dosing group died, while both 12 hours before and 7 days after the virus infection had a zero mortality rate. In particular, the clinical symptom score on the second day of administration showed an outstanding improvement of 75% compared to that of the control group even when the drug was administered after the clinical symptoms deteriorated on the 7^th day of infection.

“We will focus all our capabilities on accelerating clinical trials by preparing Phase 2 and Phase 3 IND while securing Phase 1 results so that we can develop COVID-19 treatments as soon as possible,” said Sengho Jeon, CEO of Daewoong Pharmaceutical. “We will strive to develop treatment such as Niclosamide and Camostat while expanding research and development for viral infectious diseases,” he added.

“Niclosamide is an ingredient that has proven to have excellent effects on COVID-19, and we expect that there will be a high possibility of suppressing complications in patients with severe infections as well as anti-viral effects,” said Min-seok Lee, CEO of Daewoong Therapeutics. “We will work with Daewoong Pharmaceutical to do our best in various research and development to develop it as an effective treatment for additional viral infectious diseases,” he stated.

The post Daewoong Pharmaceutical obtains approval for clinical trials of the COVID-19 drug ‘Niclosamide’ in Korea appeared first on Daewoong Indonesia.

Daewoong Foundation Charity Event 2019

zpdaewoong — Thu, 07 Nov 2019 08:04:59 +0000

To show Daewoong’s seriousness in providing the best for the people of Indonesia, Daewoong Pharmaceutical, together with Daewoong Foundation and CGBio, a Daewoong affiliated company, held a medical charity activities, as a form of collaboration between Daewoong and the Jakarta Fire Department involving collaboration of doctors from Indonesia to treat burns and spine injuries, on 24-25 October 2019. It is a form of Daewoong support to ensure Jakarta firefighters can do their job as best as they can.

The post Daewoong Foundation Charity Event 2019 appeared first on Daewoong Indonesia.

EDUCATION PROGRAM – FOR DAEWOONG FOUNDATION SCHOOLARSHIP AWARDEE 2019

zpdaewoong — Tue, 05 Nov 2019 07:29:39 +0000

This month (October 2019), Daewoong-UI Biotechnology Research center has held education program event for Daewoong Foundation scholarship awardee from Universitas Indonesia and Institut Teknologi Bandung. This event is a sequence of Daewoong Foundation Scholarship program as contribution from Daewoong for student’s education and to strengthen the cooperative relationship between Daewoong and recipient universities. The event raised a theme on Biosimilar because of its high interest from biopharmaceutical industry

This event consisted of two main event. On the first day, Thursday 10^th October 2019, Daewoong created a seminar, entitled “Embracing Biosimilar for Global Health Improvement; The Critical Point of Biosimilar”. This seminar was attended by around 25 students from several majors of Universitas Indonesia and took place in Daewoong Bio Technology Research Centre, Universitas Indonesia. The seminar consisted of 2 session. In the first session, Mr Lee Eui Nam, as Head of Researcher DW-UI explained about introduction of biosimilar. In the second session, the presentation is presented by Mr. Dhaval Patel, as Business Development Specialist of Waters Pacific Pte Ltd, one of well-known company in pharmaceutical field. Mr Dhaval Patel explained about Analytical Method Development in Biopharmaceutical using HPLC to LC-MS instruments. After all presentation finished, there were discussion between students and speakers. The discussion between the students and the speakers was very interactive and fun. The students actively asked questions about the topic presented by the speakers. For ITB awardees, Daewoong created a webinar that can be joined by awardees via online application. The purpose was to assure the ITB awardees could still join the program and get full-benefit of material presented by speakers in this seminar. The next day on Friday 11^thOctober 2019, workshop session was held and attended by 34 students of Universitas Indonesia. The workshop was divided into 2 sessions. In the first session, the awardees were given the opportunity to conduct laboratory hands-on directly under the supervision of research and development officer as mentor. They learned Ultrafiltration-Diafiltration process for protein using simple microconcentrator to Lab-Scale TFF instrument, and HPLC analysis using Reverse Phase to Size Exclusion Chromatography methods. The awardees were full of excitement doing the laboratory works and most of them actively asked the question about the topic. They showed high curiosity about the instrument that was being explained by the mentors.

The post EDUCATION PROGRAM – FOR DAEWOONG FOUNDATION SCHOOLARSHIP AWARDEE 2019 appeared first on Daewoong Indonesia.

NABOTA at IMCAS Bali 2019

zpdaewoong — Thu, 26 Sep 2019 01:54:01 +0000

Picture 1. Nabota booth at IMCAS Bali 2019

IMCAS Bali 2019

IMCAS (International Master Course on Aging Sciences) is dedicated to achieving the highest quality of teaching through the interface of plastic surgery and dermatology. IMCAS has become one of the most important international courses dedicated to aging skin treatments. There are 104 scientific sessions covering the most recent developments in 15 key themes, which include face, breast & body surgery, clinical dermatology, peelings, genital treatments, hair restoration, regenerative medicine and lipofiling, lasers & EBD. This IMCAS held on July, 5-7^th, 2019 at The Westin Resort Nusa Dua Bali, Indonesia.

Nabota (Natural Botulinum toxin Type A) was developed with Daewoong’s 30 years of experience in Biotechnology. Nabota ensures the quality of international standards via its own patented purification process (patented registration KR-10 1339349 patented in 2013). Nabota is highly purified product manufactured with a patented purification process from which impurities are removed as much as possible. Excellence in quality of Nabota has led to contracts the finished product to about 90 countries including the United States and 28 European country. Nabota has more than 98% purity resulted from Hi-Pure purification technology, and it is officially approved by FDA on February 2019. Nabota has completed phase III in US FDA, EU EMEA and Canada, which proven efficacy & safety with clinical studies over 2,000 patients.

Picture 2. Dr. Hema Sundaram Class on Daewoong Symposium

Daewoong Symposium at IMCAS

During the IMCAS, Nabota has symposium which have a theme Global Perspectives on New Botulinum Toxin: Advancing Result, Safety and New Injection Technique Based on Anatomy with the speaker Dr. Hema Sundaram (Dermatologist from USA), Pr. Seungho Han (Anatomist from Korea), Dr. Wonwoo Choi (Dermatologist from Korea). Beside the symposium, we also had 15-min Industry Lecture in open stage with speaker Pr. Seongtaek Kim with the theme Application of Nabota in Bruxism and Tempromandibular Disorder (TMD) Treatment, and we also had Pr. Seungho Han who speak about Botulinum toxin Injection: Upper Face Anatomy to avoid Side Effects.

Picture 3. Wrap up NAF Session class

Nabota Aesthetic Forum (NAF)

Nabota Aesthetic Forum (NAF) held on July, 6^th, 2019 at The Grand Hyatt Nusa Dua, Bali. It was participated by 19 doctors (3 doctors from Thailand, 1 doctor from Vietnam, 7 doctors from Philippine, 4 doctors from Indonesia, and 5 doctors from Korea). We had 9 sessions on NAF, which are NABOTA: Injection for shoulder contouring and sleep bruxism; clinical trials by Prof. Seongtaek Kim, Combining Surgical and Non-surgical Modalities for Jaw Contouring – Indian Scenario by Dr. Viral Ramesh Desai (Plastic Surgeon, India), Nabolift Injection Techniques by Dr. Wonwoo Choi (Wells Dermatology Clinic, Korea), Consideration on Botox Antibody Formation by Dr. Hyungseok Ko (Samsunglohas Clinic, Korea), Strong Efficacy of Nabota, Clinical Studies and Result in Vietnam by Dr. Pham Xuan Hung (Plastic Surgeon, Vietnam).

In the night session we had Botulinum Toxin Injection; Upper Face Anatomy to Avoid Side Effects by Prof. Seongho Han (Chung-Ang Univ, Korea), Comparison of Botulinum Toxin; Preliminary Study by Dr. Minchul Kang (Centrum Ryn Clinic, Korea), Lip Filler with Botulinum Toxin for Perioral Rhytides by Dr. Jaeun Doh (EG Dong An Clinic, Korea), Paradoxical Massetheric bulging after Botulinum Toxin injection: Basis and Prevention by Dr. Ruecha Rassamechote (Dermatologist Thailand). After the closing we had dinner together with participant and speaer doctors and also Daewoong staff at Pasar Senggol, Grand Hyatt, Bali.

Picture 4. Photo booth corner at Nabota booth

Picture 5. Nabota team Daewoong HQ and Daewoong Indonesia

The post NABOTA at IMCAS Bali 2019 appeared first on Daewoong Indonesia.

CADAVER Course with i-Class Anatomy in Thailand

zpdaewoong — Thu, 26 Sep 2019 01:27:08 +0000

Picture 1. Participant doctors from Indonesia with dr. Matt Stefanelli

iClass Anatomy

iClass Anatomy is dedicated to the teaching of relevant clinical anatomy for invasive & non-invasive aesthetic procedures. iClass Anatomy runs cadaver course, video anatomy, live injections course and 1-to-1 trainings worldwide. It was #5^thiClass Cadaver Course in Thailand, and the 2^nd time for Daewoong Pharmaceutical Co.,Ltd made this event. It was held on August 13-14^th,2019 at Siriraj Hospital, Thailand. The first day it was for training and live demo injection, and the second day it was full day of Cadaver course.

The 5^th iClass Anatomy was attended by 60 participant doctors from Thailand, Korea, China, and Indonesia. This event organized by iClass Anatomy in collaboration with Daewoong Pharmaceutical Co.,ltd and Department of Dermatology and Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. The first day of this course was 1 day full training and live demo. The training all about anatomy which divided into 2 session. Session 1 for surface anatomy, fat compartments, and vascular system. Session 2 for facial muscles, bony structures, and nervous system. All participant doctors, especially Indonesian doctors were satisfied with the lecture, they said they got new knowledge of injection techniques, especially for nerve block technique, and anesthesia technique. Besides, the speakers are very communicate, it makes participant doctors can fully understood the information which have been given by the speakers. In the first day, we also had product presentation of Nabota and Perfectha.

Picture 2. Live demo session with Dr. Mart Maiprasert and Dr. Sarawalai Rakchart

LIVE DEMO SESSION

During the workshop at the first day, we also had a live demo session which guided by Dr. Mart Maiprasert and Dr. Sarawalai Rakchart, and moderator by Assoc. Prof. Rungsima Wanitphakdeedecha and also accompanied by dr. Matt Stefanelli. In the live demo session shows the injection technique of Filler and Botulinum toxin, and divided into 2 sessions, session 1 was for Safe and Effective techniques for facial rejuvenation with 3-D virtual technology of Temple, forehead, and periorbital area. The second session was shows for area periorbital area, nose, and neck.

Picture 3. Indonesian Doctors Certification photo after Cadaver Course with the trainer doctors

CADAVER COURSE

The cadaver course done by allocation one table 1 cadaver for 5 doctors and accompanied by 1 anatomist doctor and 1 fellowship doctor from Mahidol University. The cadaver was so fresh, but the age is too old, then it may cause some of the structure of skin anatomy had a little bit different with their daily patient. Doctors felt satisfied with the course, and they feel it was great experience to attend workshop like this, because they can really learn so much technique and really get the new knowledge since they could be practice and saw directly about the anatomy face structure by real.

ANOTHER DOCUMENTATION DURING CADAVER COURSE

Picture 4. Wrap up workshop day-1

Picture 5. Certification photo after Cadaver Course

The post CADAVER Course with i-Class Anatomy in Thailand appeared first on Daewoong Indonesia.

35 UI Students and 20 ITB Students Received Daewoong Foundation Scholarship

zpdaewoong — Mon, 13 May 2019 03:20:16 +0000

In addition to help improve the quality of health of the Indonesian people, Daewoong has also taken active steps to advance Indonesian education. Through the Daewoong Foundation, this was realized by providing a total scholarship worth USD 55,000 to outstanding students who were studying at the University of Indonesia (UI) and the Bandung Institute of Technology (ITB).

The selection of the scholarship program was conducted in April 2019 with a series of stages, first file selection (application form, motivation letter, CV, etc.), followed by interview, and individual presentation with theme ‘The Role of Biopharmaceutical / Biological Drug in the Development of Indonesian National Healthcare, Now and Future’. The final selection process resulted in the selection of 20 ITB students from the School of Pharmacy, the School of Technology and Biology, and the Faculty of Industrial Engineering and 35 UI students from the Faculty of Pharmacy, Faculty of Mathematics and Natural Sciences, Faculty of Engineering, and Faculty of Medicine.

Mr. Lee Eui Nam – Head of Researcher of DW

The scholarships were given by the representative of Daewoong Indonesia, Mr. Lee Eui Nam as Chief Research of the Daewoong Company Indonesia, and ITB and UI representatives, in a ceremony held on April 26, 2019, at the ITB-Rapim A Rectorate Building, Bandung for ITB and on 29 April 2019 at Ruang Apung UI, Depok for UI. In addition to receiving education funding of USD 1000, the scholarship awardees will also receive training/education program by the Daewoong RnD team in July and December 2019, in order to improve their skill and[RI1] knowledge about recent biotechnology.

[RI1]improve their skill and

The post 35 UI Students and 20 ITB Students Received Daewoong Foundation Scholarship appeared first on Daewoong Indonesia.

SIGNING CEREMONY OF INDONESIA SURGICAL PRODUCTS DISTRIBUTION AGREEMENT WITH PT KALBE FARMA Tbk.

zpdaewoong — Wed, 20 Feb 2019 01:23:23 +0000

In the beginning of 2019, CG Bio Co., Ltd., a global Bio company is accelerating its overseas expansion.

On last February 15^th, CG Bio Co., Ltd., through PT Daewoong Pharmaceutical Company Indonesia which manages medical devices business in Indonesia had signing a distribution agreement for bone graft material products with PT Kalbe Farma, No. 1 pharmaceutical company in Indonesia. This agreement with total amount around 20 billion won (equals ± 250,6 billion rupiah) is as a stepping stone to enter Southeast Asia market.

This agreement includes Bongros and Bongener product, which is a bone healing products that consist of mineral and growth factors. These products are CG Bio’s representative products and No. 1 products in bone graft material market in Korea.

At the signing ceremony held in Jakarta, February 15^th 2019, which was attended by Director of PT Kalbe Farma, Michael Buyung Nugroho and Chief of Representative of Daewoong Pharmaceutical Co., Ltd., in Indonesia, Richard Yang, it was agreed to do a cooperation for distribution of bone graft material products for 5-year plan.

PT Kalbe Farma is the biggest local Indonesia pharmaceutical company in the field of drugs and medical devices with total annual sales around 1,7 trillion won (equals ± 21,3 trillion rupiah) with more than 17,000 employees. PT Kalbe Farma has occupied no. 1 market share in Indonesia market and known as one of the top-ranked pharmaceutical company in Southeast Asia. Moreover, PT Kalbe Farma also have their own drugs and medical devices products in orthopedic field and gain their own market as well. Through this cooperation, it is expected to have a successful collaboration with CG Bio as a company which has product pipeline for tissue regeneration that combine growth factors, biomaterial, and ceramic through an innovative research.

CEO of CG Bio, Hyun-Seung, Ryu, said “We hope through this agreement will enable us to successfully start our business in Indonesia which has unlimited development potential.” In additional, he said “In the future, we will launch some additional products with successful clinical data in Korea, since we would like to contribute to improve Indonesian quality of life and the development of medical care in Indonesia. Moreover, we are planning to have some volunteer activity and education program for local people.” At the moment, we are planning to do a social activities for burn patients in Medan on September and starting from this March we would like to build global network so that Indonesian doctors can have opportunity to get some education training in Korea. We expect to contribute to the development of local medical technology by providing high quality education program.

The post SIGNING CEREMONY OF INDONESIA SURGICAL PRODUCTS DISTRIBUTION AGREEMENT WITH PT KALBE FARMA Tbk. appeared first on Daewoong Indonesia.